Gaining Respect, New Methodologies, And Life After NICE: An Interview With Michael Rawlins
Executive Summary
Sir Michael Rawlins talks about his views on EuroNICE, PCORI and the future of health technology assessment as he prepares to step down after nearly 14 years as chairman of the U.K.'s cost regulator, the National Institute for Health and Clinical Excellence.
You may also be interested in...
Value-Based Pricing Could Boost Global Applicability Of NICE Appraisals
Value-based pricing will start in the U.K. in January 2014 for newly launched products, with prices taking into account innovation and societal benefit as well as NICE's usual clinical and cost-effectiveness analysis, U.K. Health Secretary Andrew Lansley tells NICE's annual conference.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Pipeline Watch: Phase III Readouts For Dry Eye, Menopause
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: